{"created":"2023-06-19T11:22:44.712103+00:00","id":677,"links":{},"metadata":{"_buckets":{"deposit":"880b8c9e-b907-427a-bd66-9de4712f6b24"},"_deposit":{"created_by":12,"id":"677","owners":[12],"pid":{"revision_id":0,"type":"depid","value":"677"},"status":"published"},"_oai":{"id":"oai:jichi-ir.repo.nii.ac.jp:00000677","sets":["14:32"]},"author_link":[],"item_2_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2002-12","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"101","bibliographicPageStart":"97","bibliographicVolumeNumber":"30","bibliographic_titles":[{"bibliographic_title":"自治医科大学紀要"},{"bibliographic_title":"Jichi Medical University Journal","bibliographic_titleLang":"en"}]}]},"item_2_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"慢性骨髄性白血病高齢患者に対するメシル酸イマチニブ療法において，有効性や\n安全性はまだ不明の点がある。我々は80歳以上の慢性骨髄性白血病患者３例に対して\nイマチニブ療法を経験した。２例でcomplete cytogenetic response が，１例でminor\ncytogenetic response が得られた。但し，浮腫や白血球減少などの有害事象により，\n100～200mg/d への減量が必要であった。","subitem_description_type":"Abstract"}]},"item_2_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"names":[{"name":"Matsuyama, Tomohiro","nameLang":"en"}]},{"names":[{"name":"Gono, Takahisa","nameLang":"en"}]}]},"item_2_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"自治医科大学"}]},"item_2_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1881-252X","subitem_source_identifier_type":"PISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"松山, 智洋","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"五野, 貴久","creatorNameLang":"ja"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-13"}],"displaytype":"detail","filename":"自治医科大学紀要1881-252X(30)p97-101.pdf","filesize":[{"value":"959.2 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"自治医科大学紀要1881-252X(30)p97-101","url":"https://jichi-ir.repo.nii.ac.jp/record/677/files/自治医科大学紀要1881-252X(30)p97-101.pdf"},"version_id":"9da64e3e-fcd0-4c5a-9638-a4c77077e44d"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"慢性骨髄性白血病","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"メシル酸イマチニブ","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"超高齢者","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"chronic myeloid leukemia","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"imatinib mesylate","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"very elderly patients","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"80歳以上の慢性骨髄性白血病患者に対する メシル酸イマチニブ療法","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"80歳以上の慢性骨髄性白血病患者に対する メシル酸イマチニブ療法","subitem_title_language":"ja"},{"subitem_title":"Imatinib mesylate therapy in patients aged over 80 years with chronic myeloid leukemia","subitem_title_language":"en"}]},"item_type_id":"2","owner":"12","path":["32"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2019-08-13"},"publish_date":"2019-08-13","publish_status":"0","recid":"677","relation_version_is_last":true,"title":["80歳以上の慢性骨髄性白血病患者に対する メシル酸イマチニブ療法"],"weko_creator_id":"12","weko_shared_id":-1},"updated":"2023-08-25T06:07:48.195383+00:00"}